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Heterozygous mutations of the NRXN1 gene, which
encodes the presynaptic cell-adhesion molecule
neurexin-1, were repeatedly associated with autism
and schizophrenia. However, diverse clinical presen-
tations of NRXN1 mutations in patients raise the
question of whether heterozygous NRXN1mutations
alone directly impair synaptic function. To address
this question under conditions that precisely control
for genetic background, we generated human ESCs
with different heterozygous conditional NRXN1 mu-
tations and analyzed two different types of isogenic
control and NRXN1 mutant neurons derived from
these ESCs. Both heterozygous NRXN1 mutations
selectively impaired neurotransmitter release in
human neurons without changing neuronal differ-
entiation or synapse formation. Moreover, both
NRXN1 mutations increased the levels of CASK, a
critical synaptic scaffolding protein that binds to
neurexin-1. Our results show that, unexpectedly, het-
erozygous inactivation of NRXN1 directly impairs
synaptic function in human neurons, and they illus-
trate the value of this conditional deletion approach
for studying the functional effects of disease-associ-
ated mutations.
INTRODUCTION
Autism Spectrum Disorders (ASDs) and schizophrenia impose
major disease burdens. Recent advances revealed a complex
genetic landscape in neuropsychiatric disorders (reviewed in
Murdoch and State, 2013; Giusti-Rodrı´guez and Sullivan, 2013).
Mutations in hundreds of genes with high effect sizes were iden-
tified (O’Roak et al., 2012; Sanders et al., 2012; Neale et al., 2012;
Purcell et al., 2014; Fromer et al., 2014). However, many of these
mutations are so rare that their association with a particular dis-
ease was not statistically significant. Thus it often remained un-316 Cell Stem Cell 17, 316–328, September 3, 2015 ª2015 Elsevier Iclear whether a particular mutation was directly related to a spe-
cific disorder, and whether haploinsufficiency of a gene actually
produces a direct functional impairment.
Several candidate ASD genes encode proteins involved in
synapse development and/or function. Among these, NRXN1
was significantly associated with both ASDs and schizophrenia
in many studies (reviewed in Su¨dhof, 2008; Doherty et al.,
2012; Clarke and Eapen, 2014). The NRXN1 gene encodes neu-
rexin-1, a presynaptic cell-adhesion molecule that binds to
postsynaptic cell-adhesion molecules such as neuroligins and
LRRTMs, which were also associated with ASDs or schizo-
phrenia. Most NRXN1mutations are heterozygous copy number
variations (CNVs) that delete only NRXN1 due to the large size of
the NRXN1 gene, while missense and truncation mutations are
less frequent (for recent papers, see Enggaard Hoeffding et al.,
2014; Gauthier et al., 2011; Todarello et al., 2014). Although
NRXN1 gene mutations are rare (0.18% of schizophrenia pa-
tients; Rees et al., 2014), this frequency translates into thou-
sands of patients. As a result, NRXN1 mutations at present
represent the most frequent single-gene mutation in schizo-
phrenia. Moreover, NRXN1 gene polymorphisms have been
associated with differential responses to antipsychotic medica-
tion in schizophrenia (Souza et al., 2010; Lett et al., 2011), further
buttressing the link between NRXN1 and schizophrenia. How-
ever, the effects of heterozygous NRXN1 mutations on synaptic
transmission in human neurons are unknown.
Neurexin-1 is an evolutionarily conserved presynaptic cell-
adhesion molecule (Ushkaryov et al., 1992; Tabuchi and Su¨dhof,
2002). Vertebrates express three neurexin genes (NRXN1,
NRXN2, and NRXN3 in humans), each of which includes sepa-
rate promoters for longer a- and shorter b-neurexins (Ushkaryov
et al., 1992; Ushkaryov and Su¨dhof, 1993; Tabuchi and Su¨dhof,
2002; Rowen et al., 2002). Moreover, neurexins are alternatively
spliced at six canonical sites, generating >1,000 protein isoforms
(Ullrich et al., 1995; Treutlein et al., 2014). Triple Nrxn1a/2a/3a
knockout (KO) mice exhibit severe impairments in synaptic
transmission and die at birth (Missler et al., 2003), while triple
Nrxn1b/2b/3b KO mice display alterations in endocannabinoid
signaling (unpublished data). Recordings in acute hippocampal
slices revealed discrete changes in synaptic transmission, but
not neurotransmitter release, in homozygous Nrxn1a KO micenc.
(Etherton et al., 2009). No studies analyzing cultured neurons
from either homo- or heterozygous Nrxn1a or Nrxn1b KO mice
are available, and the role of specifically NRXN1 in synaptic
transmission remains unclear.
With the advent of induced pluripotent stem cells (iPSCs), it
has become feasible to analyze neurons from patient-derived
iPSCs. Multiple studies have proved the utility of this approach
(reviewed in Hanna et al., 2010; Han et al., 2011; Bellin et al.,
2012; Imaizumi and Okano, 2014). Moreover, recent studies
showed that mutations in patient-derived iPSCs can be cor-
rected by genomic manipulations (Raya et al., 2009; Zou et al.,
2009; Howden et al., 2011). However, many ASD- and schizo-
phrenia-associated mutations exhibit incomplete penetrance,
suggesting that genetic background effects significantly influ-
ence the clinical presentation and could contribute to the
observed phenotypes. This issue is particularly relevant for
NRXN1 mutations, which have been associated with several
different neuropsychiatric disorders (Ching et al., 2010; reviewed
in Su¨dhof, 2008; Doherty et al., 2012; Clarke and Eapen, 2014).
Here we assessed the functional significance of a heterozy-
gous disease-associated mutation on human neurons by intro-
ducing heterozygous conditional NRXN1 mutations into human
embryonic stem cells (ESCs). This approach allowed us to
analyze the functional effects of NRXN1 mutations on synaptic
transmission in neurons derived from the mutant ESCs. We
found that heterozygous loss-of-function NRXN1 mutations
had no effect on neuronal differentiation and synaptogenesis,
but they severely impaired neurotransmitter release in a
stimulus-dependent pattern. This phenotype was specific to
human neurons as mouse Nrxn1a mutations exhibited no
phenotype in comparable experiments.Moreover,NRXN1muta-
tions increased the levels of CASK, a synaptic membrane
associated guanylate kinase (MAGUK) that binds to neurexin-1
(Hata et al., 1996). Our findings demonstrate that heterozygous
NRXN1mutations have profound but selective effects on synap-
tic transmission, demonstrating a haploinsufficiency phenotype
in human cells and suggesting a potential mechanism for
the role of NRXN1 mutations in ASD and schizophrenia
pathogenesis.
RESULTS
Generation of Human ESCs with Heterozygous
Conditional NRXN1 Mutations
Although hundreds of ASD and schizophrenia cases with hetero-
zygous NRXN1mutations have been described and constitutive
mouse mutants for Nrxn1a (which encodes the major transcript
of the Nrxn1 locus) were reported, no functional analyses
of cultured neurons from hetero- or homozygous Nrxn1a KO
mice are available, and no mouse mutants of the entire Nrxn1 lo-
cus were described. The only available data are from slice phys-
iology experiments suggesting a small impairment in synaptic
transmission in homozygous Nrxn1a KO mice (Etherton et al.,
2009). Thus, it is unknownwhether heterozygous or homozygous
Nrxn1 mutations in mice produce a synaptic or non-synaptic
neuronal phenotype.
To address this gap in our understanding, we analyzed cortical
neurons cultured from littermate wild-type and heterozygous
and homozygous Nrxn1a KO mice. However, we detected noCell Schange in spontaneous miniature excitatory postsynaptic cur-
rents (mEPSCs) or action-potential evoked excitatory postsyn-
aptic currents (EPSCs) in hetero- or homozygous Nrxn1a KO
neurons (Figure S1). These results suggest that Nrxn1a is not
essential for excitatory synaptic transmission in cultured mouse
cortical neurons, but they do not rule out the possibility of a more
severe human-specific effect.
Thus, to test whetherNRXN1mutationsmay potentially have a
more severe phenotypic effect in human neurons than in mouse
neurons, we used recombinant adeno-associated viruses (AAVs)
to introduce conditional mutations into the NRXN1 gene in hu-
man H1 ESCs (Kohli et al., 2004). We separately introduced
two different NRXN1 mutations and obtained correctly targeted
clones with recombination frequencies of 5%–10% (correct
clones/total clones), verified by PCR screening and Southern
blot analysis (Figures 1A and S2). Both mutations produce
loss-of-function alleles (see below) and control for each other.
For the first of the two NRXN1 mutations (the conditional
knockout [cKO]), we flanked exon 19 with loxP sites. Exon 19
is the first exon that is shared by all NRXN1 transcripts (Tabuchi
and Su¨dhof, 2002). After homologous recombination, the
mutated NRXN1 allele carries a selectable marker surrounded
by FRT sites and loxP sites that flank both exon 19 and the
selectable marker (Figure 1A). Flp-recombinase deletes the
selectable marker, allowing wild-type expression of neurexin-1
(control), while Cre-recombinase deletes exon 19, disrupting
the reading frame of the NRXN1 mRNA and blocking NRXN1
expression (KO; Figure 1B).
Because there are no working antibodies that specifically
detect neurexin-1 protein in human cells, we pursued a second
NRXN1 mutagenesis strategy that introduces an epitope tag
into neurexin-1 and additionally generates a conditional loss-of-
function mutation. In this second mutation (referred to as condi-
tional truncation [cTr]), we inserted into exon 24 (Tabuchi and
Su¨dhof, 2002) a cassette containing tandem HA epitopes, a
loxP site, a stop codon, and a polyadenylation signal, followed
by an FRT-flanked selectable marker (a puromycin resistance
cassette) and another loxP site (Figure 1A). Flp-recombinase
deletes the selectablemarkerbut retains thestopcodon, produc-
ing a truncatedHA-tagged neurexin-1 protein. Cre-recombinase,
conversely, generates a control NRXN1 allele encoding HA-
tagged full-length neurexin-1 (Figure 1B). The inserted stop
codon in the cTr mutation mimics a de novo mutation (G1402fs)
found in a schizophrenia patient that truncates neurexin-1 protein
25 residues C-terminal to the cTr mutation (Gauthier et al., 2011).
Generation of NRXN1 Mutant Human Induced Neurons
We converted ESCs with conditional NRXN1 mutations into
induced neurons (iN cells) using forced expression of the tran-
scription factor Ngn2 (Figure 1B). This method produces a ho-
mogenous, well-characterized population of excitatory cortical
neurons (Zhang et al., 2013). During iN cell differentiation, we
co-expressed the appropriate recombinases with Ngn2 in the
ESCs to produce precisely matching sets of control and hetero-
zygous NRXN1mutant iN cells (Figure 1B). We analyzed iN cells
derived from one cKO mutant and two cTr mutant ESC clones.
We observed efficient conversion of all genetically altered
ESCs into iN cells, with expression of recombinases in virtually
100% of iN cells (Figure S3). mRNA measurementstem Cell 17, 316–328, September 3, 2015 ª2015 Elsevier Inc. 317
Figure 1. Gene Targeting in Human ESCs and Generation of NRXN1 Mutant iN Cells
(A)NRXN1 targeting strategy. In the conditional knockout (cKO) strategy (left), we flanked the first exon shared by all neurexin-1 isoforms (exon 19) with loxP sites
and inserted an FRT-flanked PGK-puromycin resistance cassette (PGK-puro). In the conditional truncation (cTr) strategy (right), we inserted a cassette containing
two HA epitopes, a loxP site, a stop codon, and a polyadenylation signal followed by an FRT-flanked PGK-puro cassette and another loxP site in-frame into the
beginning of exon 24, the last NRXN1 coding exon (see sequences below the diagram). All gene modifications were introduced by AAV-mediated homologous
recombination in H1 ESCs and validated by PCR and Southern blotting (Figure S2).
(B) Procedure for generating precisely matching control and NRXN1 mutant iN cells from targeted conditionally mutant ESCs (top; schematic of the overall
procedure and the recombinase applications used for the two different mutations; bottom, flow diagram of the overall procedure).
(legend continued on next page)
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demonstrated that the cKO reduces NRXN1 mRNA levels
approximately 2-fold (Figure 1C). No effect of NRXN1mutations
on neuronal differentiation was detected, as indicated by un-
changed dendritic and cellular morphological properties (Figures
1D, 1E, and S4).
Immunocytochemistry and immunoblotting showed that in
control iN cells from cTr mutant ESCs (i.e., Cre-recombinase
treated cTr iN cells), full-length HA-tagged neurexin-1 was abun-
dantly expressed and displayed on the neuronal surface (Fig-
ure S3). Without Cre-recombinase treatment (i.e., in cTr iN cells
treated with inactive Cre-recombinase), HA-tagged full-length or
truncated neurexin-1 was neither detectable by immunocyto-
chemistry on the neuronal surface nor observed by immunoblot-
ting in the cell lysate or the media. Thus, full-length HA-tagged
neurexin-1 appears to be trafficked normally to the neuronal
cell surface in control cTr neurons, whereas truncated HA-
tagged neurexin-1 is unstable and degraded in mutant cTr
neurons. Similarly, mRNA measurements in control and mutant
neurons from NRXN1 cKO ESCs failed to detect the mutant
mRNA despite robust expression of wild-type mRNA, suggest-
ing that the mutant mRNA is rapidly degraded by nonsense-
mediated decay (Figure S3).
Next, we performed electrophysiological recordings in
matched control and NRXN1 mutant iN cells to measure funda-
mental parameters, such as membrane capacitance, input
resistance, resting membrane potential, neuronal excitability,
and voltage-dependent Na+ and K+ currents responsible for
action potential generation.We detected no differences between
correspondingNRXN1mutant andcontrol neurons in either cKO-
or cTr mutantNRXN1 iN cells (Figures 2 and S5). These data sug-
gest that lossof oneNRXN1 allele does not lead tomajor changes
in the measured non-synaptic properties of human neurons.
Heterozygous NRXN1 Mutations Decrease the
Frequency of Spontaneous mEPSCs in Human Neurons
without Affecting Synapse Density
We next asked whether heterozygous NRXN1 mutations alter
synapse formation or function, again monitoring the effects of
both mutations under precisely controlled conditions. We first
measured mEPSCs. Strikingly, we found that both the cTr and
the cKONRXN1mutation caused an2-fold decrease inmEPSC
frequencywithout altering themEPSCamplitude (Figures3A–3C).
A change in mEPSC frequency suggests a presynaptic alter-
ation in the number of synapses and/or their release probability.
To differentiate between these two possibilities, we performed a
morphological analysis of synapse numbers and dendritic arbor-
ization in NRXN1 mutant iN cells.
We sparsely labeled control and NRXN1 mutant iN cells with
lentivirusesexpressing fluorescentmarkers (EGFPor TdTomato),
immunostained the neurons for synapsin-1, and examined the
size and arborization of dendrites as well as the density, size,
and labeling intensity of synapses (Figures 3D, 3E, and S6).
Neither NRXN1 mutation altered any of these parameters,
suggesting that the NRXN1 mutations did not impair neuronal(C) NRXN1 mRNA measurements show that the heterozygous NRXN1 cKO dec
mRNAs spanning exon 19. Data are means ± SEM (n = 3). Statistical analyses we
(D and E) Representative images of iN cells produced from targeted ESCs and imm
D, 40 mm in E). For analysis of HA-tagged NRXN1 protein produced by cTr iN cells
Cell Sdevelopment or synaptogenesis. Thus, the decreased mEPSC
frequency observed in NRXN1 mutant neurons is not due to a
decrease in synapse numbers.
Heterozygous NRXN1 Mutations Impair Evoked
Neurotransmitter Release but Not the Readily
Releasable Pool of Vesicles
To analyze synaptic function in heterozygous NRXN1 mutant
neurons in more detail, we measured evoked EPSCs mediated
by AMPA-type glutamate receptors (AMPARs). Consistent with
the decrease in mEPSC frequency, we observed an 2-fold
decrease in EPSC amplitude in cTr and cKO mutant neurons
compared to corresponding control neurons (Figure 4A). This
surprisingly large effect was not due to the viral expression of
recombinases because the two different NRXN1 mutations
depend on different recombinases (Figure 1A) and expression
of various recombinases in naive human neurons had no effect
on EPSC amplitudes (Figure S7).
The decreased mEPSC frequency, normal synapse numbers,
and reduced evoked EPSC amplitudes suggest that the NRXN1
mutations decrease neurotransmitter release probability. To
further explore this possibility, we analyzed short-term synaptic
plasticity, which represents an indirect measure of release prob-
ability (Regehr, 2012).
We found that both heterozygous NRXN1 mutations signifi-
cantly decreased only the first EPSC response during a 10 Hz
stimulus train (Figure 4B). As a result, normalized plots of EPSCs
as a function of stimulus number showed that mutant neurons
exhibited significantly less synaptic depression. In accordance
with the decreases in mEPSC frequency and EPSC amplitude,
this finding strongly indicates that conditional NRXN1mutations
cause a selective large decrease in the initial neurotransmitter
release probability in human neurons, but not in the release prob-
ability overall. This decrease is not due to changes in the size of
the readily releasable pool (RRP) of synaptic vesicles, which can
be measured as the cumulative EPSC elicited by a hypertonic
sucrose stimulus (Rosenmund and Stevens, 1996), because
we detected no change in the RRP size between control and het-
erozygous NRXN1 mutant neurons (Figure 4C). Importantly, the
two different mutations (the ‘‘cTr’’ and ‘‘cKO’’ mutations; Fig-
ure 1A) exhibited indistinguishable phenotypes.
Heterozygous NRXN1 Mutation Phenotype Is
Independent of the Neuronal Differentiation Protocol
Our analyses of NRXN1 mutations used the iN cell protocol for
generating neurons (Zhang et al., 2013), which differs from tradi-
tional methods of converting ESCs into neurons via neural pre-
cursor cell (NPC) intermediates (e.g., see Zhang et al., 2001;
Wu et al., 2007; Chambers et al., 2009; Koch et al., 2009).
Because the phenotype of heterozygous NRXN1 mutations in
iN cells was surprisingly severe when compared to the lack of
a phenotype in similar mouse mutants (Figure S1), we asked
whether this phenotype may be specific to neurons produced
by the iN cell method.reases total NRXN1 mRNA levels nearly 2-fold as measured by qRT-PCR of
re performed by Student’s t test comparing test samples to control (*p < 0.05).
unolabeled with MAP2 (D,NRXN1 cTr#1 line; E, cKO line; scale bars, 50 mm in
and additional immunolabeled images of cKO iN cells, see Figures S3 and S4.
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Figure 2. Intrinsic Membrane Properties Are Not Changed in NRXN1 Mutant iN Cells
(A) Summary graphs of the passive membrane properties (in both A1 and A2: left, capacitance; middle, input resistance; right, resting membrane potential) of
control and NRXN1 mutant iN cells derived from the NRXN1 cKO (A1) or the cTr#2 line (A2).
(B) Neuronal excitability in control and NRXN1 mutant iN cells is unchanged. Left, representative traces of action potentials induced by step current
injections (from5 pA to +50 pA); right, intensity-frequency plots in the number of action potentials as a function of step current injections (B1, cKO line; B2, cTr#2
line).
(C) Representative traces of spontaneous action potentials recorded from control and NRXN1 mutant iN cells.
(D) Summary graphs of action potential properties in control and NRXN1 mutant iN cells (in both D1 and D2: left, firing threshold; middle, action potential
amplitude; right, spontaneous firing frequency).
(legend continued on next page)
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We differentiated NRXN1 cKO ESCs into a mixed population
of excitatory and inhibitory neurons using a traditional protocol
(Figures 5A and 5B; Zhang et al., 2001; Wu et. al, 2007; Koch
et al., 2009). Comparative gene expression analyses of NPC-
derived neurons and iN cells using qRT-PCR of select genes
both for bulk total mRNA (Figure 5C) and for single-cell mRNA
analyzed on a fluidigm chip (Figures 5D and 5E; see Pang
et al., 2011) demonstrated that gene expression in the two types
of human neurons was overall rather similar. Both expressed
comparable levels of the pan-neuronal marker Tuj1 and of the
telencephalic progenitor marker FOXG1 and cortical layer 2/3
marker BRN2, whereas the layer 6 marker TBR1 was more
strongly induced in NPC-derived neurons than in iN cells (Fig-
ure 5C). Expression of other regional markers, such as ASCL1
and LBX1, was comparably low in both neuronal types. The
excitatory presynaptic markers vGlut1 and vGlut2 were similarly
induced in both types of neurons, whereas the inhibitory presyn-
aptic marker vGAT was expressed 1,000-fold more strongly in
NPC-derived neurons than in iN cells, consistent with the pro-
duction of inhibitory neurons only by the traditional protocol (Fig-
ures 5C–5E). Strikingly, NRXN1a was expressed at 100-fold
higher levels than NRXN1b in both types of neurons (Figures
5D and 5E). Thus, neurons produced from NPC intermediates
were cortical in nature similar to iN cells and primarily expressed
neurexin-1a, motivating us to analyze theNRXN1mutant pheno-
type in these neurons.
We found that the phenotype of NPC-derived NRXN1 mutant
human neurons was indistinguishable from that of NRXN1
mutant iN cells, with no changes in intrinsic electrical properties
but a decrease in EPSC amplitude and a selective loss of EPSC
size during the first response in a 10 Hz stimulus train (Figures
6A–6C). Thus, the heterozygous NRXN1 deletion causes the
same phenotype in NPC-derived human neurons as in human
iN cells, validating the accuracy of that phenotype and demon-
strating that iN cells can be used as a useful preparation for
the analysis of neuronal phenotypes.
Heterozygous NRXN1Mutations Increase CASK Protein
Levels in Human Neurons
To explore the molecular basis for the decreased initial release
probability in NRXN1 mutant human neurons, we tested for
gene expression changes in mRNAs and proteins that are critical
for synaptic function, adhesion, and signaling. We found no
significant change in mRNA levels as far as we analyzed,
including CASK mRNAs (Figure 7A). For the protein analyses,
we were limited to human synaptic marker proteins with
validated antibodies. Strikingly, we observed a 60%–80% in-
crease in the levels of CASK protein in both cKO and cTr
NRXN1 mutant iN cells (Figures 7B–7D). This increase was
observed with two different antibodies and in both cKO and
cTr mutant neurons.
CASK is a cytoplasmic scaffolding protein that interacts with
neurexins (Hata et al., 1996). Mutations in the CASK gene are(E) Voltage-dependent Na+ (INa
+) and K+ (IK
+) currents are unchanged. Representa
and current/voltage plots are shown at the bottom. Currents were recorded i
from 90 mV to +20 mV at 10 mV intervals was delivered.
‘‘1’’ and ‘‘2’’ panels depict data for the NRXN1 cKO and the cTr#2 line, respective
SEM (numbers in bars or brackets show number of cells/cultures analyzed).
Cell Sassociated with ASDs, X-linked mental retardation, and brain
malformations (Najm et al., 2008; Hackett et al., 2010; Sanders
et al., 2012), suggesting that regulation of CASK levels is critical
for normal brain function. Since we found that CASK mRNA
levels were normal in NRXN1 mutant neurons (Figure 7A), the
increased CASK protein levels in NRXN1 mutant neurons sug-
gest that the synthesis or stability of CASK protein is enhanced
by the decrease in neurexin-1 levels. The magnitude of the
effect is surprising, given that only a single allele of the three
biallelic human NRXN genes was mutated. No other protein
tested was reproducibly altered, consistent with the observed
lack of a change in neuronal morphology and synapse density
(Figure 3).
DISCUSSION
Heterozygous NRXN1mutations are among the more frequently
observed single-genemutations predisposing carriers to schizo-
phrenia and ASDs, and they are additionally associated with
other neuropsychiatric disorders (Su¨dhof, 2008; Doherty et al.,
2012; Clarke and Eapen, 2014; Be´na et al., 2013; Ching et al.,
2010; Rees et al., 2014). Despite their importance, however, it
is unclear how heterozygous NRXN1 mutations predispose
human patients to neuropsychiatric diseases. This question is
particularly pungent because in mouse, homozygous Nrxn1a
mutations cause only a minor phenotype in acute hippocampal
slices (Etherton et al., 2009) and no significant phenotype in
cultured cortical neurons (Figure S1).
To address this question, we introduced two different condi-
tional loss-of-function mutations into human ESCs: a conditional
exon deletion that causes a frameshift and disrupts both neu-
rexin-1a and neurexin-1b (the cKO mutation) and a conditional
truncation of neurexin-1a and -1b that introduces a stop codon
into the protein N-terminal to the transmembrane region and
results in a secreted protein that is rapidly degraded (the cTr
mutation; Figures 1A and S3). Although most clinical NRXN1
mutations affect only NRXN1a, some alter both NRXN1a and
NRXN1b, and our cTr mutation closely mimics a schizophrenia
patient-associated mutation (Enggaard Hoeffding et al., 2014;
Gauthier et al., 2011).
The two heterozygous conditional NRXN1 mutations pro-
duced a severe and selective, indistinguishable synaptic pheno-
type in human neurons. Specifically, we detected a striking
decrease in presynaptic neurotransmitter release in NRXN1
mutant neurons that manifested as a reduction in spontaneous
mEPSC frequency, but not amplitude, and as a parallel decrease
in evoked EPSC amplitude (Figures 3, 4, and 6). At the same
time, the mutations did not alter the electrical properties of hu-
man neurons (Figure 2 and Figure S5) or their synapse numbers
and dendritic arborization (Figure 3 and Figure S6). The key fea-
tures of the NRXN1 heterozygous mutant phenotype were
observed in two different types of human neurons: iN cells that
are composed of a homogeneous population of excitatorytive traces are shown on top (insets = Na+ currents on an expanded timescale)
n voltage-clamp mode; cells were held at 70 mV; stepwise depolarization
ly. For data from the cTr#1 line, see Figure S5. All summary data are means ±
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Figure 3. Heterozygous NRXN1 Mutation Decreases the Frequency of Spontaneous mEPSCs without Altering Neuronal Morphology or
Synapse Numbers
(A–C) HeterozygousNRXN1mutations uniformly decrease themEPSC frequency approximately 2-fold. Top: representative traces recorded from iN cells derived
from the NRXN1 cKO line (A) or the two different cTr lines (B and C); bottom: summary plots and graphs of the frequency (left) and amplitudes (right) of mEPSCs.
Quantitations are shown both as cumulative probability plots and as bar diagrams (inserts).
(D) Morphological properties are unchanged in NRXN1mutant human neurons (left: representative images of control and NRXN1mutant cTr#1 iN cells that were
sparsely infected with lentiviruses expressing tdTomato to label individual neurons [scale bar, 40 mm]; right: quantifications of the total neurite length, number of
primary processes, neurite branch points, and cell size in control and NRXN1 mutant iN cells).
(E) Synapse density is unchanged in NRXN1 mutant human neurons (left: representative images of isolated control and mutant cTr#1 iN cells that were co-in-
fected with GFP and stained for the synaptic marker synapsin-1 [scale bar, 5 mm]; right: quantification of the density, staining intensity, and size of synapses in
control and mutant iN cells).
Data are means ± SEM; numbers of cells/cultures analyzed are shown in the bars. Statistical significance (**p < 0.01; ***p < 0.001) was evaluated with the
Kolmogorov-Smirnov test (cumulative probability plots) and Student’s t test (bar graphs). Figure S6 shows a similar characterization of the other lines of NRXN1
mutant ESCs.neurons (Zhang et al., 2013), and a more heterogeneous popula-
tion of neurons generated by a standard method involving an
NPC intermediate (Zhang et al., 2001).
The phenotype of the human heterozygous NRXN1mutations
is broadly consistent with previous work in mouse neurons322 Cell Stem Cell 17, 316–328, September 3, 2015 ª2015 Elsevier I(Missler et al., 2003; Etherton et al., 2009) but exhibits two unex-
pected features. First, it is surprisingly severe. In human neurons
that express 100-fold more NRXN1a than NRXN1b (Figure 5),
the heterozygous NRXN1 mutations caused an almost 2-fold
decrease in EPSC amplitude (Figures 4 and 6), whereas inmousenc.
Figure 4. Heterozygous NRXN1 Mutations Decrease the Initial Probability of Neurotransmitter Release, but Not the Size of the Readily
Releasable Pool
(A) Evoked EPSC amplitudes are decreased approximately 2-fold by heterozygous NRXN1 mutations (in A1–A3: left, representative traces; right, summary
graphs of the amplitudes of EPSCs evoked by isolated action potentials in control and NRXN1 mutant iN cells as indicated).
(B) Heterozygous NRXN1 mutations selectively impair only the first EPSC in response to a 10 Hz stimulus train (in B1–B3: top, representative traces; bottom,
summary plots of the absolute [left] and relative [right] EPSC amplitudes normalized to the first response).
(C) Heterozygous NRXN1mutations do not alter the size of the readily releasable pool as measured by the amount of release induced by an application of 0.5 M
hypertonic sucrose for 20 s (in C1–C3: left, representative traces; right, summary graphs of the synaptic charge transfer; numbers in bars indicate the number of
cells/cultures analyzed).
The ‘‘1,’’ ‘‘2,’’ and ‘‘3’’ subpanels show results separately performed with control and mutant iN cells from the cKO and the two different cTr lines to demonstrate
reproducibility as indicated. Data are means ± SEM. Numbers in bars or brackets show number of cells/independent cultures analyzed. Statistical significance
(*p < 0.05; **p < 0.01) was determined by Student’s t test (A) or the Mann-Whitney rank sum t test (B).neurons the homozygous Nrxn1aKO caused no change in EPSC
amplitude (Figure S1). Second, the decrease in EPSC amplitude
produced by heterozygous NRXN1mutations in human neurons
was rapidly alleviated during a stimulus train, i.e., the phenotype
did not consist of a general decrease of the release probability,
but exhibited a specific decrease in release probability for only
the first stimulus (Figures 4 and 6). The observation of the
same phenotype in two types of human neurons obtained by
different methods strengthens the notion that heterozygous
loss of NRXN1 gene leads to selective impairments in synaptic
transmission.
Whatmechanismunderlies thisunusualphenotypeof heterozy-
gous NRXN1 mutant human neurons? The most straightforwardCell Shypothesis for this phenotype is an impairment in presynaptic
Ca2+ influx during an action potential. Such an impairment would
impair release only initially in a high-frequency stimulus train
because of the accumulation of residual Ca2+ later in the train.
Although this phenotype differs from that observed previously in
triple a-neurexin KOmice, it is consistent with longstanding ideas
about neurexin function derived from these mice (Missler et al.,
2003). Our results thus suggest that heterozygous NRXN1muta-
tions may predispose to schizophrenia and other neuropsychi-
atric disorders by impairing synapse function in a highly specific
manner that may be amenable to pharmacological intervention.
In addition to the synaptic phenotype in heterozygous NRXN1
mutant neurons, we observed a dramatic increase in CASKtem Cell 17, 316–328, September 3, 2015 ª2015 Elsevier Inc. 323
Figure 5. Generation of Control and Heterozy-
gous NRXN1 Mutant Human Neurons using a
Standard Differentiation Protocol Involving
NPC Intermediates
(A) Flow diagram of the differentiation protocol
(modified from Zhang et al., 2001). hESCs, human
embryonic stem cells; EBs, embryoid bodies.
(B) Representative images of neural rosettes (day 12),
NPCs (day 20), and neurons (day 40) obtained as
described in (A). Cells were immunostained for the
indicatedmarkers (scale bars asmarked). In neurons,
synaptic markers (synapsin-1, homer, and vGAT in
green) were co-stained with MAP2 (red). DAPI is
indicated in blue.
(C) Comparative analysis reveals similar gene
expression patterns in human neurons generated by
iN cell and NPC-intermediate based protocols. Data
showmRNA levels of the indicated genes (normalized
for those of GAPDH [dotted line]) measured by qRT-
PCR in total RNA isolated from control cells (an un-
related iPSC line) and the two different kinds of
neurons (day 23 from Ngn2-iN cells and day 40 from
NPC-neurons). Data are means ± SEM (*p < 0.05 by
Student’s t test).
(D and E) Analysis of gene expression in single neu-
rons using qRT-PCR. Total cytosol was aspirated
from patched iN cells or NPC-derived neurons and
mRNA levels were measured on a fluidigm chip for
the indicated genes, including separate assays for
NRXN1a and NRXN1b. Data are shown for individual
cells as a heatmap (D) or in a bar diagram as means ±
SEM for all cells (E; normalized toMAP2 levels [dotted
line] and shown on a logarithmic scale; *p < 0.05 by
Student’s t test).
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Figure 6. Heterozygous NRXN1 cKO Im-
pairs Evoked Excitatory Synaptic Re-
sponses in Human Neurons Derived by a
Standard Differentiation Protocol
All data are from human neurons generated from
NRXN1 cKO ESCs as shown in Figure 5A, with
lentiviral expression of Flp- or Cre-recombinases
at day 20.
(A) Input resistance and capacitance values are
identical in control and NRXN1 cKO neurons.
(B) ESPCs evoked by isolated action potentials
exhibit an2-fold decrease in amplitude inNRXN1
cKO neurons (left, representative traces; right,
summary graphs).
(C) EPSCs evoked by a 10 Hz stimulus train exhibit
a decreased initial amplitude, but subsequent
normal amplitudes in NRXN1 cKO neurons (top,
representative traces; bottom left, summary plot of
absolute EPSC amplitudes; bottom right, summary
plot of normalized amplitudes to illustrate the
apparent decrease in synaptic depression).
Data are means ± SEM; numbers in graphs
represent number of total cells/independent cul-
tures analyzed. Statistical analyses were per-
formed by Student’s t test (A and B) or the
Mann-Whitney rank sum t test (C) comparing
test samples to control (*p < 0.05, **p < 0.01,
***p < 0.001).protein levels (Figure 7), validating the interaction of neurexin-1
with CASK (Hata et al., 1996). It seems likely that neurexin-1 nor-
mally regulates CASK levels, which might be critical for control-
ling neurotransmitter release; indeed, constitutive CASKdeletion
in mice results in an increased mESPC frequency in cortical neu-
rons (Atasoy et al., 2007). Interestingly, mutations in the human
CASK gene are also associated with ASDs, mental retardation,
and brain malformations, similar to NRXN1 mutations (Najm
et al., 2008; Hackett et al., 2010; Sanders et al., 2012).
We believe that our results may provide a significant
advance not only in our understanding of how NRXN1 muta-
tions predispose carriers to schizophrenia and ASDs, but
also in developing technologies for analyzing the biological sig-
nificance of gene mutations observed in neuropsychiatric dis-
eases. It is puzzling that many independent gene mutations
were detected in schizophrenia and ASDs; many of these mu-
tations are so rare that their significance is difficult to evaluate
(O’Roak et al., 2012; Sanders et al., 2012; Purcell et al., 2014;
Fromer et al., 2014). The approach used here allows direct
testing of whether or not a given heterozygous mutation has
a significant functional effect on at least a subset of neurons,
with the underlying notion that any mutation with a functional
effect in human neurons is likely pathogenic. Thus, our
approach may be generally applicable to the large-scale anal-
ysis of mutations observed in human patients, especially those
mutations that are rare and for which patient-derived materials
are limited.Cell Stem Cell 17, 316–328, SSeveral potential concerns about our
study may be raised. First, given the loca-
tion of the cKOmutation, is it possible that
the NRXN1 cKO we use produces a trun-
cated protein thatmay have residual func-tions or exert a dominant-negative activity? We believe that this
is highly unlikely because the mutant cKO mRNA is not detect-
able, suggesting that it is degraded by nonsense-mediated
decay (Figure S3), and because the cTrmutation did not produce
a stable truncated protein, probably because that protein is also
unstable (Figure S3). Thus, the cKO and the cTr mutations are
both effectively loss-of-functionmutations. Second, is it possible
that the Cre- and Flp-recombinase manipulations we perform to
produce NRXN1mutant and control iN cells from the same ESC
clone induce toxicity and create part of the observed pheno-
type? We believe this is improbable because the Cre- and Flp-
manipulations do not create a phenotype when instituted with
wild-type ESCs (Figure S7) and because Cre induces the loss-
of-function state in the NRXN1 cKO but prevents the loss-of-
function state in the NRXN1 cTr (Figure 1B). Third, is it possible
that the genomic condition of the ESCs we use or that clonal var-
iations among ESCsmay contribute to the phenotype? Although
the particular genetic background of the ESCswe used (H1 cells)
could have significantly contributed to the phenotype we
observed, we observed the same phenotype analyzed in
different clones and different mutations of the same gene. This
consistency documents that the phenotype is specifically
induced by the NRXN1 mutation and rules out clonal variation,
but does not exclude a possible enabling contribution by genetic
background effects in H1 cells. It will be interesting in future ex-
pansions of the current iN cell/mutagenesis approach to
compare the phenotype produced by NRXN1 mutations ineptember 3, 2015 ª2015 Elsevier Inc. 325
Figure 7. HeterozygousNRXN1 Inactivation Stabilizes CASKProtein
Levels in Human Neurons
(A) Quantifications of selected total mRNA levels in matched control versus
NRXN1 mutant iN cells as measured by qRT-PCR. Average DCt values
(normalized to synapsin-1 mRNA) were converted to a ratio of control/mutant
and plotted on a logarithmic scale.
(B and C) Quantifications of protein levels in control iN cells and in iN cells
with heterozygous NRXN1 mutations (Syt1, synaptotagmin-1; Cpx 1/2, com-
plexin-1 and -2; Syb2, synaptobrevin-2). Protein levels were determined by
quantitative immunoblotting using fluorescently labeled secondary antibodies
(B, representative immunoblots; C, summary graphs). NeuN was used as a
loading control.
(D) Quantifications of CASK protein levels in control andNRXN1mutant human
neurons using a different antibody to CASK that was used from (B) and (C). iN
cells from both clones with heterozygous cTr NRXN1 mutations and neurons
obtained by a standard protocol (Figure 5) were analyzed.
All quantitative data are normalized for the controls analyzed in parallel and
expressed as means ± SEM (n = 3–5 independent cultures). Statistical ana-
lyses were performed by Student’s t test comparing test samples to control
(*p < 0.05).
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approach to dissect genetic background effects in patient-
derived iPSCs.
The experiments described here thus suggest new avenues to
analyze the biological significance of rare disease-associated
mutations. Moreover, our approach provides insight into the
similarity of disease pathways produced by different types of
mutations. In addition, our data show in human neurons that het-
erozygousNRXN1mutations produce a functional impairment in
synaptic transmission, raising the possibility of therapeutic inter-
ventions at later, post-developmental stages in life even though
ASDs and schizophrenia are considered neurodevelopmental
disorders. Finally, the experiments described here show that
neurons produced by the iN cell method and by traditional
NPC-dependent methods exhibit similar NRXN1 mutant pheno-
types, suggesting that iN cells are reasonable experimental sub-
strates that can in principle be generated in copious amounts for
large-scale screening experiments.
EXPERIMENTAL PROCEDURES
General Procedures
All experiments were performed under anonymized sample conditions and
independently repeated multiple times. All animal experiments were approved
by the Stanford animal use committee.
ESCs
H1 ESCs were obtained from WiCell Research Resources (Wicell, WI) and
used at intermediate (50) passage numbers. ESCs were maintained as
feeder-free cells in mTeSR1 medium (Stem Cell Technologies).
Viruses
Cloning of AAV targeting constructs and of lentiviral vectors is described in
detail in the Supplemental Experimental Procedures. Lentiviruses and AAVs
were produced as described (Pang et al., 2010; Xu et al., 2012); for details
and vector sequences, see Supplemental Experimental Procedures.
Transduction of ESCs using AAVs
Transduction of ESCs using AAVs was performed essentially as described
(Kohli et al., 2004). Cells were then selected in puromycin (1 mg/ml) contain-
ing mTeSR1 medium until independent clones emerged. Clones were
manually picked under sterile conditions and transferred to 24-well or
12-well dishes in mTeSR1+puromycin and further grown until confluence.nc.
Cells were harvested and prepared for frozen stocks or genomic DNA preps
for genotyping.
Generation of iN Cells from Naive and Genetically Engineered
Human ESCs
iN cells were generated from ESCs according to Zhang et al. (2013) as
described in detail in the Supplemental Experimental Procedures. From day
6, 50% of the medium in each well was exchanged every 2–3 days. FBS
(2.5%) was added to the culture medium on day 10 to support astrocyte
viability, and iN cells were assayed on day 23 in most experiments.
Primary Cultures of Neurons from Neurexin-1a KO Mice
Primary cultures of neurons from neurexin-1a KO mice (Missler et al., 2003)
were performed and analyzed electrophysiologically as described (Maximov
and Su¨dhof, 2005).
Neural Differentiation via NPC Intermediates
Neural differentiation via NPC intermediates was performed as described
(Figure 5A; Zhang et al., 2001; Wu et. al, 2007; Koch et al., 2009) with the mod-
ifications described in the Supplemental Experimental Procedures. Differenti-
ated neurons were maintained with half medium change every 5 days until
day 40 for analysis.
Morphological Analyses
Immunofluorescence labeling experiments were performed and analyzed as
described (Pang et al., 2011; Anderson et al., 2012). For analysis of dendritic
arborizations, iN cells were sparsely infected with lentiviruses expressing
tdTomato to obtain fluorescent images of individual neurons. Image acquisi-
tion and analysis were performed as described (Anderson et al., 2012). See
Supplemental Experimental Procedures for details.
Electrophysiological Recordings
Electrophysiological recordings in cultured iN cells were performed in the
patch-clamp whole-cell configuration as described (Maximov and Su¨dhof,
2005; Zhang et al., 2013; for details, see Supplemental Experimental
Procedures).
Gene Expression Analyses
Qualitative and quantitative RT-PCR analyses of cultured cells were performed
in bulk on total RNA using Superscript-III Reverse Transcriptase reaction (Invi-
trogen; RT-PCR) and a one-step reaction (Roche) and an Applied Biosystems
7900HT apparatus (qRT-PCR). To ensure the specificity of the amplification,
titrations of total human brain RNA were used to eliminate primers without a
linear amplification relation. Single-cell qRT-PCR was performed using fluid-
igm methods (Pang et al., 2011). For details and PCR primer sequences, see
Supplemental Experimental Procedures.
Immunoblotting and Protein Quantifications
Immunoblotting and protein quantifications were performed with fluorescently
labeled secondary antibodies and an Odyssey Infrared Imager and Odyssey
software (LI-COR Biosciences). Signals were normalized for NeuN probed
on the same blots as loading controls. For antibody details, see Supplemental
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes seven figures and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2015.07.017.
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